Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.
Nicolas LeupinPier Luigi Luigi ZinzaniFranck MorschhauserStéphane DalleMarie MaerevoetJean Marie MichotVincent RibragFritz OffnerMarie Beylot-BarryHélène Moins-TeisserencKaren ZwaenepoelKoen de WinneMaxime BattistellaAnna HultbergDomenica GandiniMahan MoshirJulie JacobsTim DelahayeAitzaz KhanPiotr ZabrockiKaren SilenceLuc van RompaeyChristophe BorgGiovanna MottaFederica MelleAngelica CalleriPatrick PauwelsHans de HaardStefano PileriMartine BagotPublished in: Cancer (2021)
Cusatuzumab was well tolerated, and antitumor activity was observed at both 1 and 5 mg/kg in highly pretreated patients with R/R CTCL. The observed dose-dependent effect on exposure supports the use of 5 mg/kg for future development.